Bright Minds Biosciences (id:579 DRUG)
47.37 CAD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/23/2024 2:26:57 AM)
Exchange closed, opens in 2 days 7 hours
About Bright Minds Biosciences
Market Capitalization 391.41M
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.
| Headquarters (address) |
19 Vestry Street New York 10013 NY United States |
| Phone | 647 407 2515 |
| Website | https://brightmindsbio.com |
| Employees | 0 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | DRUG |
| Exchange | Canadian Securities Exchange |
| Currency | CAD |
| 52 week range | 1.29 - 108.00 |
| Market Capitalization | 391.41M |
| P/E trailing | 0.319 |
| Price/Book | 41.08 |
| Beta | 1.13 |
| EPS | -0.880 |
| EPS United States (ID:6, base:3401) | 24.26 |